Zydus Lifesciences targets USFDA filing for Saroglitazar 2026

What Zydus announced and why it matters

Zydus Lifesciences Ltd said its US-based arm, Zydus Therapeutics, has reported encouraging late-stage results for saroglitazar in primary biliary cholangitis (PBC). The study, EPICS-III, evaluated the drug in adults with PBC, described as a rare and progressive liver disease. Zydus said it plans to file for US regulatory approval in early 2026, and separately specified the first quarter of 2026 for the USFDA submission. For investors, the update is a clear regulatory milestone tied to a late-stage asset with positive topline data. For patients and clinicians, it signals potential progress in a setting where options can be limited, particularly for those who cannot use standard therapy. The company also highlighted that saroglitazar has USFDA Orphan Drug and Fast Track designations, which can support development and review timelines. The announcement placed Zydus among a small set of drugmakers actively pursuing new PBC therapies based on phase 3 evidence.

EPICS-III trial design: who was studied

EPICS-III was described as a Phase 2b/3 clinical trial, with the pivotal readout coming from the Phase 3 component. The trial evaluated Saroglitazar Magnesium in adults with PBC. It specifically included patients who could not tolerate or did not benefit from ursodeoxycholic acid (UDCA), the usual first-line treatment noted in the report. In one account, the phase 3 part of the trial randomized 149 people to receive saroglitazar or placebo. Treatment was administered as daily oral dosing over 52 weeks. The comparator was placebo, which enables clearer measurement of biochemical improvements. The setting is clinically relevant because PBC progression is tracked using lab markers that reflect liver function and cholestasis. The design therefore focused on endpoints tied to disease monitoring rather than symptoms alone.

Primary endpoint: biochemical response versus placebo

Zydus said saroglitazar met the main study goal in EPICS-III. In the detailed trial summary, 48.5% of patients on saroglitazar 1 mg achieved a meaningful biochemical response compared with placebo. Another description of the topline results said nearly half of patients showed meaningful improvement in liver enzyme and bilirubin levels versus those on placebo. The report emphasized that these markers are widely used to track PBC progression. Meeting a primary endpoint in a late-stage trial is central to supporting a USFDA filing, particularly for rare diseases where clinical endpoints can be difficult to standardize. The result was positioned as a treatment difference after 52 weeks of dosing. Zydus also described saroglitazar as the first dual PPAR agonist to show positive phase 3 data in PBC, framing the outcome in a drug-class context. The company indicated the data could support a new option for doctors and patients, without detailing pricing or launch timelines.

Secondary endpoint and durability at 52 weeks

Beyond the primary endpoint, Zydus said saroglitazar cleared a key secondary test. The company reported that more patients achieved normalised enzyme levels after 52 weeks of treatment. This is relevant because normalization of enzymes is often used as a stronger biochemical signal than partial improvement. The trial duration of 52 weeks also matters for chronic diseases where sustained control is important. The topline descriptions did not provide exact secondary endpoint percentages, but they stated the direction of benefit versus placebo. The emphasis on week-52 outcomes suggests the company is pointing to durability, not just early response. Zydus did not disclose subgroup outcomes or response rates by baseline severity in the provided text. It also did not describe histology or imaging measures in the trial summary presented. The company’s next step remains regulatory discussions and filing preparation based on the overall dataset.

Safety: tolerability and adverse events

Zydus said saroglitazar was well tolerated in EPICS-III. The company stated side effects were similar in both the treatment and placebo groups. Another account said adverse events were balanced between saroglitazar-treated and placebo-treated groups. For late-stage liver disease trials, tolerability is a key factor because patients often take long-term therapy and may have multiple comorbidities. The topline safety summary did not list specific adverse events, discontinuation rates, or serious adverse event counts. However, the consistent messaging across reports was that there were no major safety imbalances against placebo. This type of safety profile, if supported by full data, is typically important for risk-benefit assessment during regulatory review. Zydus has not stated whether any safety monitoring concerns required protocol changes during the trial. The company’s next disclosures are likely to include more detailed safety tables when it presents complete results.

Regulatory path: USFDA filing targeted for Q1 2026

Zydus said it plans to file for US regulatory approval in early 2026, and specified a first-quarter 2026 submission. The company also said it plans to discuss the data with the US FDA, with the aim of filing in Q1 2026. Saroglitazar already holds USFDA Orphan Drug and Fast Track designations, which signal recognition of unmet need and can allow for closer agency engagement. These designations do not guarantee approval, but they can shape the review process and interactions. The filing would be led by Zydus Therapeutics, the US-based specialty arm of Zydus Lifesciences. In India, saroglitazar has been approved since 2020 for non-alcoholic fatty liver disease (NAFLD) and NASH, which provides an existing safety and usage history in another indication. The PBC filing would be a separate regulatory case based on PBC trial evidence. The company has not provided a US launch timeline in the supplied text, only the intended submission window.

Market and stock reaction: what investors saw

Shares of Zydus Lifesciences ended at ₹980.75 on the BSE on August 29, 2025, up ₹3.85 or 0.39%, following the EPICS-III update. The stock reaction was modest, but directionally positive on the day the results were reported. Separately, earlier in 2025, Zydus Lifesciences shares traded at ₹1,007.00 on the NSE at 11:09 AM, up over 5%, after another USFDA-related update tied to Sentynl Therapeutics. That update involved Priority Review for a New Drug Application for Copper Histidinate injection (CUTX-101), with a PDUFA action date of July 17, 2025. Together, these events show Zydus has multiple regulatory-facing programs in the US ecosystem through its subsidiaries. The saroglitazar news is clinical-trial driven, while the CUTX-101 update is tied to review status and timelines. Investors typically track these milestones because they can influence development costs, timelines, and potential commercialization planning. The company has not provided guidance on revenue contribution from either asset in the provided material.

Key facts at a glance

How the story fits Zydus’ broader US pipeline

The saroglitazar update comes alongside other US regulatory programs disclosed by Zydus-linked entities. In January 2025, the company said the USFDA granted Priority Review to Sentynl Therapeutics’ NDA for CUTX-101 for Menkes disease. The USFDA set a PDUFA action date of July 17, 2025 for that application, indicating an accelerated review timeline. While this is a separate drug and disease area, it highlights a pattern of using US-based subsidiaries to advance specialty and rare-disease products. In the saroglitazar case, Zydus is moving from positive late-stage PBC data toward a planned filing window. The PBC opportunity was described in one report as a market projected to reach $10.8 billion by 2026, growing at a CAGR of 36.3%, although the company did not provide its own sales projections in the text provided. The next concrete step is submission preparation and FDA interactions ahead of Q1 2026. For markets, the focus is likely to remain on publication of full EPICS-III results and any additional regulatory updates from the company.

Conclusion: what to watch next

Zydus Lifesciences, through Zydus Therapeutics, has reported positive late-stage EPICS-III data for saroglitazar in PBC, including a primary endpoint win and a supportive safety summary. The company’s stated next step is a USFDA regulatory submission targeted for the first quarter of 2026, supported by Orphan Drug and Fast Track designations. Investors will likely watch for fuller disclosure of the EPICS-III dataset, including detailed secondary outcomes and safety breakdowns, as the filing approaches. The key near-term timeline marker, based on what the company has said, is the planned Q1 2026 submission window and any FDA meeting updates that precede it.